Comparisons
Mounjaro vs. Zepbound: Same Drug, Different Label
Same question as Ozempic versus Wegovy, same shape of answer. Both are tirzepatide, both from Eli Lilly, and the difference is regulatory rather than pharmacological.
5 min read · Updated · Published by CoreAge Rx
Side by side
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| Licensed for | Type 2 diabetes | Chronic weight management; obstructive sleep apnoea with obesity |
| Dose range | 2.5 → 15 mg weekly | 2.5 → 15 mg weekly |
| Key trial programme | SURPASS (diabetes) | SURMOUNT — 20.9% at 72 weeks |
| Insurance coverage | Often covered with a diabetes diagnosis | Frequently excluded by policy |
| Approximate cash price | $1,000–$1,100/month | $1,000–$1,100/month |
Note the row that differs from the semaglutide pair: the dose ranges here are identical. There is no dose-ceiling argument between Mounjaro and Zepbound the way there is between Ozempic and Wegovy — see Ozempic vs. Wegovy: Same Drug, Different Label.
What makes tirzepatide different from semaglutide
Tirzepatide is a dual agonist: it activates the GLP-1 receptor and the GIP receptor, where semaglutide activates only GLP-1. That second receptor appears to improve how fat tissue handles energy and to blunt nausea at comparable effectiveness. It is the more powerful of the two on average — 20.9% versus 14.9% in their respective trials.
Which is right for a given person is a genuinely open question, and it is not always the more powerful one. The full comparison is in Semaglutide vs. Tirzepatide: Which Is Right for You?.
The sleep apnoea approval
Zepbound carries an indication for moderate-to-severe obstructive sleep apnoea in adults with obesity — the first medication ever approved for that condition. It followed the SURMOUNT-OSA trials, which measured breathing interruptions per hour rather than pounds. If you have an OSA diagnosis, that indication can matter for coverage as well as for treatment. See GLP-1 Medication and Sleep Apnoea.
Compounded tirzepatide, from $99/month
Same active ingredient. No insurance required. Physician review within 24 hours.
Get Started Now →✓ Starts at $99/month ✓ No insurance required ✓ Free 2-day shipping ✓ 24-hour approval
Where compounded tirzepatide fits
Compounded tirzepatide contains the same active ingredient, prepared by a licensed pharmacy. The price difference against either brand is large. The trade-offs — no FDA-approved finished product, no manufacturer trial of that specific preparation — are real, and they are set out honestly in Compounded GLP-1 Medication, Explained rather than skipped.
Common questions
Is one stronger than the other?
No. Same molecule, same dose range. The difference is entirely in what each is licensed for and how insurance treats it.
Why would a doctor pick one over the other?
Almost always coverage. A diabetes diagnosis usually points to Mounjaro; weight management or sleep apnoea points to Zepbound.
Which brand did the 20.9% figure come from?
The SURMOUNT weight-management programme, which supported the Zepbound approval. Same molecule as Mounjaro.
How does the dosing schedule work?
Six steps from 2.5 mg to 15 mg, roughly monthly. Most people do not need the top rung — see GLP-1 Dosing and Titration, Week by Week.
What does this cost without insurance?
$1,000–$1,100 a month for either brand at cash price. Compounded alternatives start at $99 — the full arithmetic is in What GLP-1 Medication Costs in 2026.
The same molecule, without the price
From $99/month. Free 2-day shipping. No long-term contract.
Get Started Now →✓ Starts at $99/month ✓ No insurance required ✓ Free 2-day shipping ✓ 24-hour approval